JP2021536494A - マグネシウム含有製剤及びその使用 - Google Patents

マグネシウム含有製剤及びその使用 Download PDF

Info

Publication number
JP2021536494A
JP2021536494A JP2021513276A JP2021513276A JP2021536494A JP 2021536494 A JP2021536494 A JP 2021536494A JP 2021513276 A JP2021513276 A JP 2021513276A JP 2021513276 A JP2021513276 A JP 2021513276A JP 2021536494 A JP2021536494 A JP 2021536494A
Authority
JP
Japan
Prior art keywords
magnesium
carnitine
source
formulation
liver disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021513276A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020049549A5 (https=
JP2021536494A5 (https=
Inventor
デイヴィッド ゼリンカー
Original Assignee
トゥドゥ ホールディングス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トゥドゥ ホールディングス リミテッド filed Critical トゥドゥ ホールディングス リミテッド
Publication of JP2021536494A publication Critical patent/JP2021536494A/ja
Publication of JPWO2020049549A5 publication Critical patent/JPWO2020049549A5/ja
Publication of JP2021536494A5 publication Critical patent/JP2021536494A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021513276A 2018-09-06 2019-06-27 マグネシウム含有製剤及びその使用 Pending JP2021536494A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL261670A IL261670B (en) 2018-09-06 2018-09-06 Magnesium-containing formulation and uses thereof
IL261670 2018-09-06
PCT/IL2019/050717 WO2020049549A1 (en) 2018-09-06 2019-06-27 Magnesium-containing formulation and uses thereof

Publications (3)

Publication Number Publication Date
JP2021536494A true JP2021536494A (ja) 2021-12-27
JPWO2020049549A5 JPWO2020049549A5 (https=) 2022-06-30
JP2021536494A5 JP2021536494A5 (https=) 2022-06-30

Family

ID=63998430

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021513276A Pending JP2021536494A (ja) 2018-09-06 2019-06-27 マグネシウム含有製剤及びその使用

Country Status (6)

Country Link
US (1) US20210322465A1 (https=)
EP (1) EP3846779A4 (https=)
JP (1) JP2021536494A (https=)
CA (1) CA3111618A1 (https=)
IL (1) IL261670B (https=)
WO (1) WO2020049549A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220265603A1 (en) * 2019-06-25 2022-08-25 National Hospital Organization Hepatic fibrosis-inhibiting agent and brown fat cell-activating agent containing taxifolin

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002542191A (ja) * 1999-04-16 2002-12-10 シグマ−タウ・ヘルスサイエンス・ソシエタ・ペル・アチオニ グルタチオンの吸収を増しかつその効果を補強するのに有用な、カルニチンおよびグルタチオン含有組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2018137C (en) * 1989-06-14 2000-01-11 Thomas Scholl L-carnitine magnesium citrate
US6608222B2 (en) * 2000-11-21 2003-08-19 Alpha Food Ingredients, Inc. Bioactive conjugated linoleic acid glycerides and method of use
US6686340B2 (en) * 2001-06-19 2004-02-03 Matthias Rath Composition and method for prevention and treatment of health conditions caused by constriction of smooth muscle cells
US20050215640A1 (en) * 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
US20130236529A1 (en) * 2012-03-09 2013-09-12 Flavitpure, Inc. Composition and methods to enhance anti-oxidation, gut flora and immunity in pets
EA201890618A1 (ru) * 2015-09-01 2018-10-31 Ферст Вэйв Байо, Инк. Способы и композиции для лечения состояний, ассоциированных с аномальными воспалительными ответами
MX2018003926A (es) * 2015-10-02 2018-09-06 Balchem Corp Composicion para mejorar el rendimiento.
KR101782134B1 (ko) * 2015-12-11 2017-09-26 (주) 머니키 카르시니아캄보지아 추출물을 함유한 건강보조식품
RU2629606C1 (ru) * 2016-08-01 2017-08-30 Федеральное государственное бюджетное образовательное учреждение высшего образования "Национальный исследовательский Мордовский государственный университет им. Н.П. Огарёва" Применение соединения магния, обладающего гепатопротекторной активностью, для лечения алкогольного и лекарственного гепатита

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002542191A (ja) * 1999-04-16 2002-12-10 シグマ−タウ・ヘルスサイエンス・ソシエタ・ペル・アチオニ グルタチオンの吸収を増しかつその効果を補強するのに有用な、カルニチンおよびグルタチオン含有組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Data from a randomizedand controlled trial of L-Carnitine prescription forthe treatment for Non-Alco", BIOINFORMATION, vol. Vokume 10(9), JPN6023023243, 2014, pages 575 - 579, ISSN: 0005275294 *
"L -Carnitine Supplementation to Diet: A New Tool in Treatment of Nonalcoholic Steatohepatitis - A R", AMERICAN JOURNAL OF GASTROENTEROL, vol. 105(6), JPN6023023244, 2010, pages 1338 - 1345, ISSN: 0005275293 *

Also Published As

Publication number Publication date
IL261670B (en) 2019-06-30
WO2020049549A1 (en) 2020-03-12
CA3111618A1 (en) 2020-03-12
US20210322465A1 (en) 2021-10-21
EP3846779A1 (en) 2021-07-14
IL261670A (en) 2018-10-31
EP3846779A4 (en) 2022-06-01

Similar Documents

Publication Publication Date Title
JP7442095B2 (ja) ベータ－ヒドロキシブチレート及びブタンジオールのｓ－エナンチオマー並びにその使用方法
JP6830359B2 (ja) 栄養組成物
JP6255079B2 (ja) シトルリンおよびアルギニンを含有する即効性血中アルギニン濃度上昇型経口剤
JP5085541B2 (ja) 疲労軽減剤
JP2022064912A (ja) 哺乳動物において筋タンパク質合成および／または機能強度を増大させる方法および組成物ならびに組成物を製造する方法
US20040043442A1 (en) Use of betaine in functional products having blood pressure lowering effects
JP5281268B2 (ja) 筋力向上剤
US20240122890A1 (en) Use of exogenous ketone esters to induce weight loss in mammals
JP2021536494A (ja) マグネシウム含有製剤及びその使用
TWI749050B (zh) 包含選自瓜胺酸、白胺酸、半胱胺酸、牛磺酸、麩胺酸及天冬胺酸所成群組的１種或２種以上之胺基酸與中鏈脂肪酸及中鏈脂肪酸酯之任一者或兩者之組成物用於人攝取促進酮體生成之使用
US20250367147A1 (en) Solid r-beta-hydroxybutyric acid composition
TW201919604A (zh) 酮體生成促進劑
JP4847732B2 (ja) 冷え症改善剤
JP2008255087A (ja) 自発運動促進剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220622

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220622

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230613

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230906

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240305